Undifferentiated (embryonal) sarcoma

This study tests a drug called lurbinectedin in people aged 10 and older whose solid tumors (like Ewing sarcoma) have returned after standard treatment. The goal is to see if the drug is safe and can shrink tumors or delay their growth. Participants must have a specific genetic c…

This study tests whether two drugs, zanzalintinib and pembrolizumab, can help control advanced soft-tissue sarcoma that has spread. About 20 adults with specific sarcoma types will receive the combination. The main goal is to check safety and see if the treatment slows tumor grow…

This early-stage trial tests a new drug called GAIA-102 in children whose neuroblastoma or other solid tumors have not responded to standard treatments. The study has four groups, testing GAIA-102 alone or combined with other cancer drugs. The main goal is to check safety and fin…

This study is for children and young adults (up to age 30) with a rare type of soft tissue cancer called non-rhabdomyosarcoma. It tests whether adding the drugs pazopanib and selinexor to standard chemotherapy can improve outcomes. Participants receive treatment tailored to their…

This study tests whether a new type of immune cell therapy (HER2-CAR T cells) combined with drugs that boost the immune system (pembrolizumab or nivolumab) is safe for people with advanced sarcoma. About 25 participants will receive chemotherapy before the cell infusion to help t…

This study tests a new combination of drugs (tislelizumab, liposomal doxorubicin, and ifosfamide) as a first treatment for people with advanced soft tissue sarcoma that cannot be removed by surgery or has spread. The goal is to see if this combo shrinks tumors and is safe. About …

This study tests a new drug called QL1706 in 45 adults with advanced bone or soft tissue sarcoma that cannot be removed by surgery or has spread. Participants receive the drug every 3 weeks. The main goal is to see if the cancer stays stable for at least 12 weeks. Researchers wil…